Production (Stage)
SAB Biotherapeutics, Inc.
SABS
$1.93
$0.126.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.02% | 19.17% | -67.46% | -38.15% | -47.21% |
| Total Depreciation and Amortization | -25.39% | 27.96% | 32.94% | 36.20% | 35.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -140.13% | -124.36% | 21.81% | 33.76% | 2,924.65% |
| Change in Net Operating Assets | 133.05% | -198.83% | -111.09% | -158.81% | -156.76% |
| Cash from Operations | 8.54% | -36.52% | -188.84% | -132.07% | -120.67% |
| Capital Expenditure | 31.74% | -71.04% | -41.56% | -39.33% | 63.27% |
| Sale of Property, Plant, and Equipment | -98.88% | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 177.73% | -- | -- | -- | -- |
| Cash from Investing | 176.43% | -7,728.66% | -10,438.18% | -8,326.63% | -3,692.23% |
| Total Debt Issued | -32.57% | -32.57% | -38.10% | -38.10% | -38.10% |
| Total Debt Repaid | -29.40% | -23.13% | -2.76% | 39.70% | 47.37% |
| Issuance of Common Stock | -100.00% | -99.97% | 676.56% | 676.84% | 669.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 44.03% | -- | -- | -- | -- |
| Cash from Financing | -101.43% | -101.76% | 780.53% | 805.29% | 852.10% |
| Foreign Exchange rate Adjustments | -1,570.59% | -1,432.60% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -961.70% | -214.81% | 214.20% | 207.08% | 110.42% |